A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Κύριοι συγγραφείς: | Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M |
---|---|
Μορφή: | Journal article |
Έκδοση: |
2011
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
ανά: Leijen, S, κ.ά.
Έκδοση: (2011) -
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
ανά: Gupta, A, κ.ά.
Έκδοση: (2013) -
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
ανά: Dummer, R, κ.ά.
Έκδοση: (2008) -
MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
ανά: Takahashi, O, κ.ά.
Έκδοση: (2009) -
Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
ανά: Jin-Hang Gao, κ.ά.
Έκδοση: (2022-03-01)